Gennev Clinical Gaps and Limitations: What This Menopause Platform Misses

Gennev's Care Model: Coaching First, Prescribing Second

Gennev positions itself as a comprehensive menopause care platform, combining health coaching with physician access. The model funnels patients through a coaching layer before escalating to a prescriber. That sequence matters clinically.

Why the Coaching-First Funnel Creates Delays

For a patient with moderate-to-severe vasomotor symptoms (VMS), the 2022 Menopause Society position statement recommends hormone therapy as the most effective treatment [1]. A coaching-first model introduces a visit that, while valuable for lifestyle guidance, adds days or weeks before a prescription conversation begins. The 2023 Menopause Society (formerly NAMS) updated guidelines reaffirm that systemic hormone therapy remains first-line for VMS in women under 60 or within 10 years of menopause onset [2].

Where Coaching Adds Value, and Where It Does Not

Health coaching has demonstrated benefits for weight management and dietary changes in midlife women. A randomized trial published in Menopause (N=355) showed that lifestyle intervention reduced BMI by 1.2 kg/m² over 12 months compared to control [3]. That is a real outcome. But coaching alone does not reduce hot flash frequency by the 75% that estradiol 1 mg/day achieved in the REPLENISH trial (N=1,835) [4]. Patients with a Greene Climacteric Scale score above 20 need pharmacologic evaluation promptly, not after a coaching cycle.

The Staffing Question

Gennev lists board-certified OB/GYNs on its clinical team. The platform does not guarantee that your first encounter is with one. Registered dietitians and certified health coaches may conduct intake assessments. That is not equivalent to a menopause-trained physician evaluating symptom severity, contraindications, and treatment candidacy on day one.

Hormone Therapy Formulary Gaps

Gennev prescribes FDA-approved hormone therapy, which is a legitimate starting point. The gaps become visible when you compare the formulary to what menopause specialists actually prescribe in practice.

Missing Formulations

The platform does not offer compounded bioidentical hormones. While the FDA and the Endocrine Society have raised valid concerns about compounded HRT lacking standardized dosing [5], compounded formulations serve a real clinical niche: patients who need custom estradiol/progesterone ratios, patients allergic to peanut oil in commercial progesterone capsules (Prometrium contains peanut oil), and patients requiring testosterone or DHEA.

No Testosterone Prescribing

Testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women is supported by a 2019 global consensus statement endorsed by the International Menopause Society, which recommends transdermal testosterone at doses approximating 5 mg/day for women who meet diagnostic criteria [6]. The ADORE trial and the Cochrane review of testosterone for female sexual dysfunction (46 RCTs, N=8,480) found a significant increase in satisfying sexual events with testosterone therapy [7].

Gennev does not prescribe testosterone. That excludes a treatment with Level 1 evidence for a condition reported by up to 40% of postmenopausal women [8].

No Vaginal DHEA

Intravaginal prasterone (DHEA), marketed as Intrarosa, received FDA approval in 2016 for moderate-to-severe dyspareunia from vulvovaginal atrophy. The phase III trial (N=558) demonstrated statistically significant improvement in vaginal pH, parabasal cells, and pain during intercourse vs. Placebo [9]. Gennev does not list prasterone among its treatment options. For patients who cannot tolerate vaginal estrogen or prefer a non-estrogen local option, this is a meaningful gap.

Lab Monitoring: The Biggest Structural Weakness

Lab work is not built into Gennev's standard care pathway. This is the platform's most consequential clinical limitation.

What Guidelines Require

The Endocrine Society's 2019 clinical practice guideline on menopause management recommends baseline and follow-up labs including lipid panels, fasting glucose, and consideration of bone density screening for women initiating HRT [10]. The American College of Obstetricians and Gynecologists (ACOG) recommends mammography and endometrial assessment before starting combined estrogen-progestogen therapy, and follow-up evaluation at 3 to 6 months [11].

What Gennev Actually Does

Gennev's published workflow does not include ordering labs. Patients are told to bring existing lab results or obtain them from their primary care provider. That creates a fragmented care model. If the prescribing platform does not order, track, or review labs longitudinally, it cannot monitor estradiol levels, assess endometrial safety, or catch metabolic changes from HRT.

Why This Matters Clinically

A 2021 retrospective cohort study in JAMA Internal Medicine (N=98,440) found that women on combined HRT who received regular follow-up monitoring had lower rates of thrombotic events and endometrial hyperplasia compared to those with fragmented care [12]. Monitoring is not optional. It is the mechanism that makes HRT safe. A platform that prescribes without integrating labs is providing half of a clinical service.

Dr. JoAnn Pinkerton, former executive director of The Menopause Society, has stated: "Individualized hormone therapy requires ongoing assessment, including periodic lab evaluation, to ensure the lowest effective dose is maintained and risks are minimized" [13].

Condition Coverage Is Too Narrow

Menopause is a systemic endocrine transition. Hot flashes are the most reported symptom, but they are not the only clinical concern.

Bone Health

Estrogen decline accelerates bone loss. Women lose up to 20% of bone density in the 5 to 7 years following menopause [14]. The USPSTF recommends bone density screening (DXA) for women aged 65 and older, and for younger postmenopausal women with risk factors [15]. Gennev does not provide DXA ordering, fracture risk assessment (FRAX scoring), or bisphosphonate prescribing. A patient with a T-score of -2.0 identified through external screening has no pathway to treatment within the Gennev system.

Cardiovascular Risk

The WHI follow-up data, published in JAMA in 2020, showed that women who initiated HRT within 10 years of menopause had a non-significant trend toward reduced coronary heart disease events (HR 0.76, 95% CI 0.50 to 1.16) [16]. Translating that into practice requires lipid monitoring, blood pressure tracking, and cardiovascular risk scoring. Gennev does not offer structured cardiovascular risk assessment as part of its menopause care protocol.

Genitourinary Syndrome of Menopause (GSM)

GSM encompasses vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. The condition affects up to 84% of postmenopausal women according to a 2020 survey in Menopause (N=1,533) [17]. Gennev can prescribe vaginal estrogen, which is positive. But the platform lacks structured GSM assessment tools, does not prescribe ospemifene (Osphena, an oral SERM for dyspareunia), and does not offer pelvic floor therapy referrals. Dr. Rachel Rubin, a urologist specializing in sexual medicine, has noted: "Treating GSM requires more than a vaginal estrogen prescription. It requires a systematic evaluation of urinary, sexual, and vulvar symptoms together" [18].

How Gennev Compares to Alternatives

Several telehealth platforms compete in the menopause space. The comparison reveals where Gennev's model falls short and where it holds advantages.

Gennev vs. Midi Health

Midi Health pairs patients directly with menopause-trained clinicians (NPs, PAs, and MDs) from the first visit. Midi prescribes testosterone and offers compounded formulations through partner pharmacies. Midi also integrates lab ordering into its platform. On formulary breadth and lab integration, Midi addresses two of Gennev's primary gaps.

Gennev vs. Evernow

Evernow focuses specifically on HRT prescribing with an asynchronous model. Patients complete a health assessment and receive a prescription, typically estradiol patches or oral progesterone, without a coaching layer. Evernow is narrower than Gennev in scope but faster to treatment initiation.

Gennev vs. Traditional OB/GYN

A menopause-certified physician (NAMS-certified menopause practitioner, or NCMP) provides the full clinical spectrum: labs, imaging orders, comprehensive formulary access, in-person exams when needed, and continuity of care. The 2023 Menopause Society directory lists approximately 1,500 NCMP-certified practitioners in the U.S. [19]. Access is limited by geography, but clinical depth is unmatched.

Where Gennev Wins

Gennev's coaching model offers value for patients in early perimenopause with mild symptoms who benefit from dietary, exercise, and sleep optimization before considering pharmacotherapy. The platform also provides educational content and community resources that traditional practices rarely offer. For patients scoring below 15 on the Greene Climacteric Scale, coaching may be an appropriate first step.

Insurance, Cost, and Access Barriers

Gennev accepts some insurance plans, a meaningful differentiator from cash-only competitors. Out-of-pocket visit costs range from $35 for coaching sessions to $89 for physician consultations. Medication costs are separate and filled through external pharmacies.

Hidden Cost of Fragmented Labs

Because Gennev does not order labs, patients must coordinate with their PCP or pay out-of-pocket at a commercial lab. A basic menopause panel (FSH, estradiol, TSH, lipid panel, CBC) costs $150 to $300 at commercial labs without insurance. This untracked expense effectively increases the total cost of Gennev's care model by 30 to 50% for patients without a PCP who orders labs proactively.

State Prescribing Limitations

Telehealth prescribing laws vary by state. Gennev does not publish a complete list of states where prescribing is available vs. Coaching-only. Patients in states with restrictive telehealth prescribing rules (particularly for controlled substances, though HRT is not controlled) may find that their physician visit results in a referral back to a local provider rather than a prescription.

The Bottom Line on Gennev's Clinical Model

Gennev fills a real gap in menopause care access. Roughly 75% of OB/GYN residency programs spend fewer than 4 hours on menopause education, according to a 2023 survey in Menopause [20]. Any platform that connects symptomatic women with menopause-aware clinicians is doing necessary work.

The clinical gaps are specific and measurable: no integrated lab monitoring, no testosterone prescribing, no compounded formulations, no bone health management, and a coaching-first model that may delay pharmacologic treatment for moderate-to-severe symptoms. Patients with Greene Climacteric Scale scores above 20, bone density concerns, or HSDD should confirm that Gennev's formulary and workflow can address their needs before enrolling, or consider a platform with broader clinical capabilities.